Can You Take Semaglutide Orally? Injection and Tablet Options Compared

Step 1: understanding why an oral semaglutide tablet is more complex than a standard pill

Semaglutide is a large peptide molecule. Swallowed on its own, stomach acid degrades it long before absorption can happen, which is why the injection bypassed that problem entirely for so long. The oral Wegovy tablet solves this by pairing semaglutide with a co-formulation agent called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate). SNAC temporarily raises the local pH around the tablet as it dissolves, protecting the molecule and allowing it to absorb through the lining of the stomach.

That mechanism creates one firm rule around how the tablet is taken: first thing in the morning, on a completely empty stomach, with no more than a small sip of plain water, up to about 120 ml. You then wait at least 30 minutes before any food, drink (including coffee or tea) or other oral medicines. Miss that window and absorption drops sharply. The Wegovy overview at nume covers both forms in more detail if you want the wider picture before deciding which route to explore.

There is no refrigeration requirement for the tablet, which matters for people who travel frequently or who find keeping a pen in the fridge awkward.

Step 2: the licensed forms and what the MHRA has actually approved

On 11 June 2026, the MHRA approved Wegovy tablets as the first oral GLP-1 medicine licensed in the UK for weight management, a meaningful milestone because the UK was the first country in Europe to grant that approval. The tablet is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity.

The once-weekly injection form of Wegovy (semaglutide 2.4 mg) has been licensed in the UK for weight management since 2023 and is recommended by NICE in technology appraisal TA875 for use within specialist weight management services. A higher 7.2 mg single-dose pen was subsequently approved by the MHRA in April 2026, providing another option in the injection lane.

A common misconception worth clearing up: some people assume Rybelsus (another oral semaglutide tablet) is the same product used for weight loss. It is not. Rybelsus (3 mg, 7 mg and 14 mg) is licensed for type 2 diabetes, not weight management, and its dosing schedule is entirely separate from the Wegovy tablet range. If you are wondering whether semaglutide can be taken orally and how the two oral products differ, that page explains the distinction clearly. The weight-loss tablet schedule runs 1.5 mg to 4 mg to 9 mg and up to a 25 mg maintenance dose, those are the only steps in that ladder.

Step 3: what the trial evidence shows for oral semaglutide

The OASIS 4 phase-3 trial enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks, comparing the oral tablet against placebo alongside lifestyle changes. The headline result, as announced with the MHRA approval in June 2026, was an average weight loss of around 13.6% for participants on the active tablet, versus around 2.4% on placebo. Among those who stayed fully adherent throughout, the average reached roughly 17%, though that figure should be read alongside the full-adherence caveat rather than as a general expectation.

The most frequently reported side effects in the trial were gastrointestinal: nausea, diarrhoea and vomiting were more common in the oral semaglutide group (around 74%) than in the placebo group (around 42%), though most were mild to moderate and tended to settle with time. This mirrors the experience many people report with the injection. The NHS medicines page for semaglutide sets out side effects for both forms in patient-friendly language and is worth reading before starting either route.

For context on how to think about the costs involved in private treatment, the cost guide for Wegovy in the UK explains what private pricing typically includes and what questions to ask any provider.

Step 4: how a prescriber decides which form might suit you

The injection and the tablet are not interchangeable for every person. A prescriber considers several practical and clinical factors: your tolerance for injections, your morning routine (the tablet's 30-minute fasting window is non-negotiable), whether you travel in circumstances where refrigeration is unreliable, your current medicines and how they interact with a morning-dose protocol, and whether you have any conditions that affect gastric motility or absorption.

People already established on the 2.4 mg weekly injection may, subject to clinical assessment, move directly to the 25 mg tablet rather than restarting the full escalation ladder, but that is a decision made with a prescriber, not a self-managed switch. Our clinical team, led by a GPhC-registered Independent Prescriber, reviews every consultation personally on the day it is submitted. There are no algorithms making that call.

If you are curious about semaglutide more broadly, the semaglutide information page covers the medicine's background, its uses and how it differs from other GLP-1 options. Men sometimes wonder whether these treatments are equally relevant for them, the page on semaglutide for men addresses that directly. And if you have questions about timing, the guidance on taking a late dose is a practical read before you start either form.

If oral semaglutide sounds like something you would like to explore, checking your eligibility is the first step. Start your free consultation with our prescribers and they will work through the clinical picture with you.